Neurocrine Biosciences, Inc. Stock price

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
137.9 USD +0.07% Intraday chart for Neurocrine Biosciences, Inc. -4.05% +4.68%
Sales 2024 * 2.21B Sales 2025 * 2.52B Capitalization 13.72B
Net income 2024 * 492M Net income 2025 * 652M EV / Sales 2024 * 5.17 x
Net cash position 2024 * 2.28B Net cash position 2025 * 3.03B EV / Sales 2025 * 4.25 x
P/E ratio 2024 *
29.4 x
P/E ratio 2025 *
22 x
Employees 1,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.73%
More Fundamentals * Assessed data
Dynamic Chart
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug MT
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults CI
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 02:00 PM
Transcript : Neurocrine Biosciences, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:00 PM
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing MT
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing MT
More news
1 day+0.07%
1 week-1.94%
Current month+5.77%
1 month+1.39%
3 months+3.89%
6 months+19.45%
Current year+4.68%
More quotes
1 week
133.43
Extreme 133.425
145.42
1 month
129.15
Extreme 129.15
148.37
Current year
128.00
Extreme 128
148.37
1 year
89.04
Extreme 89.04
148.37
3 years
71.88
Extreme 71.875
148.37
5 years
71.85
Extreme 71.85
148.37
10 years
12.17
Extreme 12.17
148.37
More quotes
Managers TitleAgeSince
Founder 66 91-12-31
Director of Finance/CFO 44 17-10-31
Chief Tech/Sci/R&D Officer 60 21-11-29
Members of the board TitleAgeSince
Director/Board Member 75 99-03-31
Director/Board Member 72 15-09-30
Founder 66 91-12-31
More insiders
Date Price Change Volume
24-03-28 137.9 +0.07% 1,245,663
24-03-27 137.8 -2.36% 1,174,119
24-03-26 141.2 +0.65% 594,739
24-03-25 140.2 -0.83% 535,108
24-03-22 141.4 -1.61% 938,631

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
137.9 USD
Average target price
151.8 USD
Spread / Average Target
+10.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Neurocrine Biosciences, Inc. - Nasdaq